Stockscreener 앱 받기
7.99
0.88%
0.07
전일 마감가:
$7.92
열려 있는:
$8.05
하루 거래량:
10.12M
Relative Volume:
2.47
시가총액:
$1.28B
수익:
$847.25M
순이익/손실:
$-284.86M
주가수익비율:
-3.4891
EPS:
-2.29
순현금흐름:
$-112.35M
1주 성능:
-2.44%
1개월 성능:
-9.31%
6개월 성능:
-38.25%
1년 성능:
+100.75%
1일 변동 폭
$7.8027
$8.54
1주일 범위
$7.70
$8.54
52주 변동 폭
$3.81
$23.86
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.99 | 1.28B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Novavax to Report Q4 Earnings: Here's What You Can Expect - MSN
Novavax (NVAX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 - Kilgore News Herald
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax COVID-19 vaccine gets green light from CDC; will be available in coming weeks - The National Desk
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal - MSN
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Consensus PT from Brokerages - MarketBeat
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $17.83 - MarketBeat
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Pending US vaccine decisions as Kennedy takes top health job - Reuters
Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider - GlobeNewswire Inc.
Novavax To Get $350 Mln For Unused COVID Shots From Canada - BW Healthcare World
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax's CEO Stanley Erck To Retire - BW Healthcare World
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
(NVAX)Analyzing Novavax's Short Interest - Benzinga
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
- GuruFocus.com
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - MSN
Zacks Research Issues Positive Forecast for Novavax Earnings - MarketBeat
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zacks Research Has Positive Estimate for Novavax Q2 Earnings - MarketBeat
Novavax (NASDAQ:NVAX) Trading Down 5.7%Time to Sell? - MarketBeat
Novavax (NASDAQ:NVAX) Shares Down 5.7%Time to Sell? - MarketBeat
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery - MSN
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit - MSN
(NVAX) Long Term Investment Analysis - Stock Traders Daily
New Strong Buy Stocks for January 30th - Yahoo Finance
Moderna stock rises following RFK Jr's comments - MSN
Nanopharmaceuticals Market Generated Opportunities, Future - openPR
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - MSN
Moderna stock rises following RFK Jr's comments By Investing.com - Investing.com South Africa
Novavax (NASDAQ:NVAX) delivers shareholders strong 122% return over 1 year, surging 11% in the last week alone - Simply Wall St
Novavax falls after guidance cut on lower vaccine sales - MSN
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position - MarketBeat
Novavax, Inc. (NVAX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Novavax (XTER:NVV1) Short-Term Capital Lease Obligation : €9.68 Mil (As of Sep. 2024) - GuruFocus.com
Novavax (XTER:NVV1) Free Cash Flow : €-112.35 Mil (TTM As of Sep. 2024) - GuruFocus.com
Novavax (NASDAQ:NVAX) Shares Up 6.1%Here's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads - Benzinga
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
| King Rachel K. | Director |
Dec 13 '24 |
Sale |
9.02 |
4,150 |
37,435 |
14,770 |
| YOUNG JAMES F | Director |
Dec 31 '24 |
Sale |
8.00 |
5,400 |
43,200 |
51,760 |
| YOUNG JAMES F | Director |
Dec 24 '24 |
Sale |
8.48 |
4,600 |
39,008 |
57,160 |
0.27%
3.05%
자본화:
|
볼륨(24시간):